I
Power Law company profile
Iovance Biotherapeutics
Biotech & Life Sciences · New York City, United States · Founded 2007 · IPO 2010 Unicorn
Valuation
$1.23B
Market cap · Apr/2026
Revenue
$264M
Latest reported FY
Global footprint
Where Iovance Biotherapeutics has talent and traffic
AI talent share
0.1%
of workforce is AI talent
(1 of 918 staff)
(1 of 918 staff)
Core AI00%
Other AI10.11%
Non-AI workforce91799.89%
Web traffic by country
22K
monthly visits
across markets
across markets
🇺🇸 United States42.3%
🇬🇧 United Kingdom9.1%
🇨🇦 Canada6.4%
🇩🇪 Germany5.9%
🇯🇵 Japan5.5%
Patent intelligence
$73M patent portfolio · 107 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$73M
6.0% of market cap · 4.3× smaller than top peer Exact Sciences ($319M)
107 active patent families
Where Iovance Biotherapeutics innovates
OncologyCancer researchTumor-infiltrating lymphocytesLymphocyteCarcinosis
Below peer median on Legal, Market
Quality vs same-sector peers
Iovance Biotherapeutics on the five Patsnap quality dimensions
Iovance Biotherapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Iovance Biotherapeutics concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Iovance Biotherapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Iovance Biotherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.